Observational studyActa neurologica Scandinavica2022
Intercountry comparisons of advanced Parkinson's disease symptoms and management: Analysis from the OBSERVE-PD observational study.
Observational study in Acta neurologica Scandinavica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 8 citations in OpenAlex.
- Impact of Uncontrolled Motor Fluctuations in Parkinson's Disease: Real-World Insights from the PROSPECT Observational Study.Advances in therapy · 2026Article
- Resolution of Levodopa/Dopa-Decarboxylase Inhibitor-Associated Microscopic Colitis with Subcutaneous Foslevodopa/Foscarbidopa: A Case Series and Review of the Literature.Movement disorders clinical practice · 2026Review
- Parkinson's disease quality of life at 12 months comparing invasive device-aided therapy with oral treatment.NPJ Parkinson's disease · 2025Article
- Grasping the big picture: impact analysis of screening tools for timely referral for device-aided therapies.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- Winding Back the Clock on Advanced Therapies: It's Time to Get Smart.Journal of Parkinson's disease · 2024Article
- Tools and criteria to select patients with advanced Parkinson's disease for device-aided therapies: a narrative review.Journal of neural transmission (Vienna, Austria : 1996) · 2023Review
- Access to device-aided therapies in advanced Parkinson's disease: navigating clinician biases, patient preference, and prognostic uncertainty.Journal of neural transmission (Vienna, Austria : 1996) · 2023Review
- Intercountry comparisons of advanced Parkinson's disease symptoms and management: Analysis from the OBSERVE-PD observational study.Acta neurologica Scandinavica · 2022Observational
- L-Dopa/Carbidopa intestinal gel infusion in advanced Parkinson's disease: real-life mobility insights from wearable sensors.Frontiers in neurologyArticle
- Smartwatch-Based Screening to Identify Candidates for Deep Brain Stimulation in Parkinson's Disease.Digital biomarkersArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 7 countries.
Funding
Abstract
objectivesIn the absence of widely accepted criteria, determining when a patient with Parkinson's disease (PD) may benefit from more advanced treatments such as device-aided therapy (DAT) so far remains a matter of physician judgment. This analysis investigates how classification of PD varies across countries relative to measures of disease severity. MATERIALS AND
methodsThe OBSERVational, cross-sEctional PD (OBSERVE-PD) study included consecutive patients with PD at centers that offer DATs in 18 countries. In this subgroup analysis, we explore intercountry differences in identification of advanced versus non-advanced PD based on physician's clinical judgment, symptoms assessed using Delphi consensus criteria, use of DAT, motor and non-motor symptoms, and caregiver support. Demographic and clinical characteristics were obtained through review of medical records.
resultsOverall, 1342 of 2615 patients (51.3%) were assessed by physicians as having advanced PD. The proportion of patients in different countries identified as having advanced PD (24.4-82.2%) varied. In 15 of 18 countries, a greater proportion of patients with advanced PD, according to select Delphi criteria, were identified by physicians as having advanced PD than with non-advanced PD. There was a wide variability across countries in the proportion of patients with no dyskinesia, disabling dyskinesia, dyskinesia pain, and non-motor symptoms who were identified by physicians as having advanced versus non-advanced PD.
conclusionsThe proportion of patients identified with advanced PD symptoms varies widely across countries, despite differences on the patients' profiles, indicating a need for objective diagnostic criteria to help identify patients who may benefit from DAT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.